Molecular Genetics and Metabolism Reports最新文献

{"title":"Partial suppression of BCAA catabolism as a potential therapy for BCKDK deficiency","authors":"Laura Ohl ,&nbsp;Amanda Kuhs ,&nbsp;Ryan Pluck ,&nbsp;Emily Durham ,&nbsp;Michael Noji ,&nbsp;Nathan D. Philip ,&nbsp;Zoltan Arany ,&nbsp;Rebecca C. Ahrens-Nicklas","doi":"10.1016/j.ymgmr.2024.101091","DOIUrl":"https://doi.org/10.1016/j.ymgmr.2024.101091","url":null,"abstract":"<div><p>Branched chain ketoacid dehydrogenase kinase (BCKDK) deficiency is a recently described inherited neurometabolic disorder of branched chain amino acid (BCAA) metabolism implying increased BCAA catabolism. It has been hypothesized that a severe reduction in systemic BCAA levels underlies the disease pathophysiology, and that BCAA supplementation may ameliorate disease phenotypes. To test this hypothesis, we characterized a recent mouse model of BCKDK deficiency and evaluated the efficacy of enteral BCAA supplementation in this model. Surprisingly, BCAA supplementation exacerbated neurodevelopmental deficits and did not correct biochemical abnormalities despite increasing systemic BCAA levels. These data suggest that aberrant flux through the BCAA catabolic pathway, not just BCAA insufficiency, may contribute to disease pathology. In support of this conclusion, genetic re-regulation of BCAA catabolism, through <em>Dbt</em> haploinsufficiency, partially rescued biochemical and behavioral phenotypes in BCKDK deficient mice. Collectively, these data raise into question assumptions widely made about the pathophysiology of BCKDK insufficiency and suggest a novel approach to develop potential therapies for this disease.</p></div>","PeriodicalId":18814,"journal":{"name":"Molecular Genetics and Metabolism Reports","volume":"39 ","pages":"Article 101091"},"PeriodicalIF":1.9,"publicationDate":"2024-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214426924000442/pdfft?md5=b366c7af33522baac93e042133fb1637&pid=1-s2.0-S2214426924000442-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140901863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Poor adherence during adolescence is a risk factor for becoming lost-to-follow-up in patients with phenylketonuria","authors":"Marianna Beghini ,&nbsp;Maximilian Pichler ,&nbsp;Fiona Carolina Tinnefeld ,&nbsp;Matthäus Metz ,&nbsp;Dorothea Möslinger ,&nbsp;Vassiliki Konstantopoulou ,&nbsp;Johannes Spenger ,&nbsp;Alexandra Kautzky-Willer ,&nbsp;Florian Frommlet ,&nbsp;Thomas Scherer ,&nbsp;Miriam Hufgard-Leitner","doi":"10.1016/j.ymgmr.2024.101087","DOIUrl":"https://doi.org/10.1016/j.ymgmr.2024.101087","url":null,"abstract":"<div><h3>Purpose</h3><p>A high rate of lost to follow-up (LTFU) in patients with phenylketonuria (PKU) represents a main challenge. In this study, we investigated potential risk factors for becoming LTFU related to adolescence as a critical period of life.</p></div><div><h3>Methods</h3><p>We retrospectively analyzed longitudinal data collected from 1993 to 2019 of patients diagnosed with classic PKU that were followed at our center during adolescence (14–18 y) and at least once in adulthood (&gt;18 y). Patients who interrupted their contact with our center after the 18th birthday for at least 2 years were classified as LTFU. We performed a multivariate regression analysis to investigate following potential risk factors for becoming LTFU in adult life: sex, dietary compliance during adolescence assessed through the mean of the annual medians of phenylalanine plasma values, average number of contacts with the center during adolescence and age at first visit after the 18th birthday.</p></div><div><h3>Results</h3><p>93 patients (52 males, 41 females) were included in the study. 58% became LTFU during adulthood. The mean age at the last visit before becoming LTFU was 26.2 ± 5.1 years. In the multivariate Cox regression analysis we found that poor dietary compliance during adolescence was significantly associated with a higher risk of becoming LTFU during adulthood (<em>p</em>-value = 0.028).</p></div><div><h3>Discussion</h3><p>Adult patients who displayed poor treatment adherence during adolescence should be identified and carefully monitored to prevent loss of contact.</p></div>","PeriodicalId":18814,"journal":{"name":"Molecular Genetics and Metabolism Reports","volume":"39 ","pages":"Article 101087"},"PeriodicalIF":1.9,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214426924000405/pdfft?md5=1508159e8abde38b8437ef90f76e7cfe&pid=1-s2.0-S2214426924000405-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140894631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severe heart failure in a unique case of cobalamin-C-deficiency resolved with LVAD implantation and subsequent heart transplantation","authors":"Clara Hjalmarsson ,&nbsp;Charlotte Backelin ,&nbsp;Anders Thoren ,&nbsp;Niklas Bergh ,&nbsp;Jennifer L. Sloan ,&nbsp;Irini Manoli ,&nbsp;Charles P. Venditti ,&nbsp;Göran Dellgren","doi":"10.1016/j.ymgmr.2024.101089","DOIUrl":"https://doi.org/10.1016/j.ymgmr.2024.101089","url":null,"abstract":"<div><p>Introduction</p><p>Cobalamin c deficiency (cblC), an inborn error of vitamin B12 metabolism, is caused by mutations of the MMACHC gene. It usually leads to a multisystemic disease; 50% of all patients with cblC have various structural heart defects. Severe congestive heart failure (HF) may also occur and its prognosis is poorly documented.</p><p>Case report</p><p>We present the case of a young man who had been diagnosed with cblC due to C331T mutation in the MMACHC gene at the age of 3 days and had been treated with substitution therapy (OH-Cbl, mecobalamine, carnitine, betaine, and calcium folinate) since then. He had mildly impaired cognitive function; an ectopic hypophysis/pituitary insufficiency, with adequate hormone replacement therapy; obstructive sleep apnea syndrome, treated with CPAP, bronchial asthma, and obesity (BMI of 30). The liver and kidney functions were normal. He developed severe dilated cardiomyopathy and HF at the age of 12y. With medical treatment, his condition improved and he was stable (NYHA class II) for several years. Six years later, his status deteriorated rapidly, as he developed advanced HF, INTERMACS 3. The cardiac ultrasound revealed dilated ventricles with severely depressed ejection fraction (EF), increased filling pressures, and pulmonary hypertension (sPAP 60 mmHg). Cardiac MRI showed extremely dilated chambers (LVedv 609 mL, RVedv 398 mL) with pronounced non-compaction, and a left ventricle EF of 13%. A primary prophylactic ICD and a left ventricular assist device (LVAD/HM3) were implanted, and the patient was subsequently listed for heart transplantation (HTx). After 25 months on the waiting list, he underwent an uncomplicated HTx. However postoperatively, he got two episodes of cardiac tamponade, as well as mediastinitis, treated with antibiotics and vaccum assisted closure. He developed severe kidney failure, which fully recovered after two months, and was treated successfully for an early moderate allograft rejection (ISHT 2). At the latest outward visit, twelve months after HTx, the patient was doing excellent.</p><p>Summary</p><p>To the best of our knowledge, this is the first ever reported case of a patient with CblC undergoing an LVAD implantation and subsequently a HTx. Although both interventions were complicated with bleeding events, this seems to be a treatment option for advanced HF in patients with CblC.</p></div>","PeriodicalId":18814,"journal":{"name":"Molecular Genetics and Metabolism Reports","volume":"39 ","pages":"Article 101089"},"PeriodicalIF":1.9,"publicationDate":"2024-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214426924000429/pdfft?md5=57ecc307f8f8a2677d25b1c08565f0d8&pid=1-s2.0-S2214426924000429-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140879378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Newborn screening for isovaleric acidemia: A case report of a Chinese patient with novel variants","authors":"Huizhong Li,&nbsp;Fang Shao,&nbsp;Wei Zhou","doi":"10.1016/j.ymgmr.2024.101088","DOIUrl":"https://doi.org/10.1016/j.ymgmr.2024.101088","url":null,"abstract":"<div><p>Isovaleric acidemia (IVA) is a rare autosomal recessive disorder that manifests as a deficiency of isovaleryl-CoA dehydrogenase (IVD), a key enzyme in leucine metabolism. The clinical presentations associated with IVD deficiency are variable and include feeding intolerance, vomiting, metabolic acidosis, ketonemia, “sweaty feet” odor, lethargy, coma and even death. Tandem mass spectrometry (MS/MS) and gas chromatography–mass spectrometry (GC/MS) methods were used to perform organic acid analysis of blood and urine samples from IVA patients, and the genetic analysis included next generation sequencing (NGS) and Sanger sequencing of the <em>IVD</em> gene. Here, we report the case of an almost seven-year-old male patient from a Chinese family who was asymptomatic during the newborn period, including the clinical manifestations and examination results. Genetic analysis revealed a previously unreported compound heterozygous variant in the <em>IVD</em> gene: c.593G &gt; C (p.W198S) and c.859C &gt; T (p.R287W).</p></div>","PeriodicalId":18814,"journal":{"name":"Molecular Genetics and Metabolism Reports","volume":"39 ","pages":"Article 101088"},"PeriodicalIF":1.9,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214426924000417/pdfft?md5=2f05e3baa5460ee91526a2add77e0bdd&pid=1-s2.0-S2214426924000417-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140824132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acid α-glucosidase (GAA) activity and glycogen content in muscle biopsy specimens of patients with Pompe disease: A systematic review","authors":"Benedikt Schoser ,&nbsp;Nina Raben ,&nbsp;Fatbardha Varfaj ,&nbsp;Mark Walzer ,&nbsp;Antonio Toscano","doi":"10.1016/j.ymgmr.2024.101085","DOIUrl":"https://doi.org/10.1016/j.ymgmr.2024.101085","url":null,"abstract":"<div><p>Pompe disease is a rare genetic disorder characterized by a deficiency of acid α-glucosidase (GAA), leading to the accumulation of glycogen in various tissues, especially in skeletal muscles. The disease manifests as a large spectrum of phenotypes from infantile-onset Pompe disease (IOPD) to late-onset Pompe disease (LOPD), depending on the age of symptoms onset. Quantifying GAA activity and glycogen content in skeletal muscle provides important information about the disease severity. However, the distribution of GAA and glycogen levels in skeletal muscles from healthy individuals and those impacted by Pompe disease remains poorly understood, and there is currently no universally accepted standard assay for GAA activity measurement. This systematic literature review aims to provide an overview of the available information on GAA activity and glycogen content levels in skeletal muscle biopsies from patients with Pompe disease.</p><p>A structured review of PubMed and Google Scholar literature (with the latter used to check that no additional publications were identified) was conducted to identify peer-reviewed publications on glycogen storage disease type II [MeSH term] + GAA, protein human (supplementary concept), Pompe, muscle; and muscle, acid alpha-glucosidase. A limit of English language was applied. Results were grouped by methodologies used to quantify GAA activity and glycogen content in skeletal muscle. The search and selection strategy were devised and carried out in line with Preferred Reporting of Items in Systematic Reviews and Meta-Analysis guidelines and documented using a flowchart. Bibliographies of papers included in the analysis were reviewed and applicable publications not already identified in the search were included.</p><p>Of the 158 articles retrieved, 24 (comprising &gt;100 muscle biopsies from &gt;100 patients) were included in the analysis, with four different assays. Analysis revealed that patients with IOPD exhibited markedly lower GAA activity in skeletal muscles than those with LOPD, regardless of the measurement method employed. Additionally, patients with IOPD had notably higher glycogen content levels in skeletal muscles than those with LOPD. In general, however, it was difficult to fully characterize GAA activity because of the different methods used. The findings underscore the challenges in the interpretation and comparison of the results across studies because of the substantial methodological variations. There is a need to establish standardized reference ranges of GAA activity and glycogen content in healthy individuals and in Pompe disease patients based on globally standardized methods to improve comparability and reliability in assessing this rare disease.</p></div>","PeriodicalId":18814,"journal":{"name":"Molecular Genetics and Metabolism Reports","volume":"39 ","pages":"Article 101085"},"PeriodicalIF":1.9,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214426924000387/pdfft?md5=7a6c91e4ce9647f2b38f21d11da753cc&pid=1-s2.0-S2214426924000387-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140646128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inherited metabolic disorders in Cyprus","authors":"Theodoros Georgiou ,&nbsp;Petros P. Petrou ,&nbsp;Anna Malekkou ,&nbsp;Ioannis Ioannou ,&nbsp;Marina Gavatha ,&nbsp;Nicos Skordis ,&nbsp;Paola Nicolaidou ,&nbsp;Irini Savvidou ,&nbsp;Emilia Athanasiou ,&nbsp;Sofia Ourani ,&nbsp;Elena Papamichael ,&nbsp;Marios Vogazianos ,&nbsp;Maria Dionysiou ,&nbsp;Gabriella Mavrikiou ,&nbsp;Olga Grafakou ,&nbsp;George A. Tanteles ,&nbsp;Violetta Anastasiadou ,&nbsp;Anthi Drousiotou","doi":"10.1016/j.ymgmr.2024.101083","DOIUrl":"https://doi.org/10.1016/j.ymgmr.2024.101083","url":null,"abstract":"<div><p>Selective screening for inherited metabolic disorders (IMD) began in Cyprus in 1990. Over the last thirty-three years 7388 patients were investigated for IMD and 200 diagnoses were made (diagnostic yield 2.7%). The existence of a single laboratory of Biochemical Genetics for the whole island facilitated the creation of a national registry for IMD. The minimal prevalence of IMD in Cyprus is 53.3 cases per 100,000 live births. The most common group are disorders of amino acid metabolism (41.0%), followed by disorders of carbohydrate metabolism (16.5%), disorders of complex molecule degradation (16.5%), mitochondrial disorders (10.5%) and disorders of vitamin and co-factor metabolism (5.5%). Hyperphenylalaninaemia is the most common IMD (14.0%) followed by galactosaemia (7.0%), glutaric aciduria type I (5.5%) and MSUD (4.0%). Some disorders were found to have a relatively high incidence in specific communities, for example Sandhoff disease among the Cypriot Maronites and GM1 gangliosidosis in one particular area of the island. Other disorders were found to have a relatively higher overall incidence, compared to other Caucasian populations, for example galactosaemia, glutaric aciduria type I and MSUD, while fatty acid oxidation defects, Gaucher disease and classic PKU were found to have a relatively lower incidence. Molecular characterization of selected disorders revealed many novel genetic variants, specific to the Cypriot population.</p></div>","PeriodicalId":18814,"journal":{"name":"Molecular Genetics and Metabolism Reports","volume":"39 ","pages":"Article 101083"},"PeriodicalIF":1.9,"publicationDate":"2024-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214426924000363/pdfft?md5=da493ed0e5e867fe2b309e87d3ea9f53&pid=1-s2.0-S2214426924000363-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140637879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pegvaliase for the treatment of phenylketonuria: Final results of a long-term phase 3 clinical trial program","authors":"Cary O. Harding ,&nbsp;Nicola Longo ,&nbsp;Hope Northrup ,&nbsp;Stephanie Sacharow ,&nbsp;Rani Singh ,&nbsp;Janet A. Thomas ,&nbsp;Jerry Vockley ,&nbsp;Roberto T. Zori ,&nbsp;Kaleigh Bulloch Whitehall ,&nbsp;Joshua Lilienstein ,&nbsp;Kristin Lindstrom ,&nbsp;Drew G. Levy ,&nbsp;Shaun Jones ,&nbsp;Barbara K. Burton","doi":"10.1016/j.ymgmr.2024.101084","DOIUrl":"https://doi.org/10.1016/j.ymgmr.2024.101084","url":null,"abstract":"<div><p>Phenylketonuria (PKU) is a genetic disorder caused by deficiency of the enzyme phenylalanine hydroxylase (PAH), which results in phenylalanine (Phe) accumulation in the blood and brain, and requires lifelong treatment to keep blood Phe in a safe range. Pegvaliase is an enzyme-substitution therapy approved for individuals with PKU and uncontrolled blood Phe concentrations (&gt;600 μmol/L) despite prior management. Aggregated results from the PRISM clinical trials demonstrated substantial and sustained reductions in blood Phe with a manageable safety profile, but also noted individual variation in time to and dose needed for a first response. This analysis reports longer-term aggregate findings and characterizes individual participant responses to pegvaliase using final data from the randomized trials PRISM-1 (<span>NCT01819727</span><svg><path></path></svg>) and PRISM-2 (<span>NCT01889862</span><svg><path></path></svg>), and the open-label extension study 165–304 (<span>NCT03694353</span><svg><path></path></svg>). In 261 adult participants with a mean of 36.6 months of pegvaliase treatment, 71.3%, 65.1%, and 59.4% achieved clinically significant blood Phe levels of ≤600, ≤360, and ≤ 120 μmol/L, respectively. Some participants achieved blood Phe reductions with &lt;20 mg/day pegvaliase, although most required higher doses. Based on Kaplan-Meier analysis, median (minimum, maximum) time to first achievement of a blood Phe threshold of ≤600, ≤360, or ≤ 120 μmol/L was 4.4 (0.0, 54.0), 8.0 (0.0, 57.0), and 11.6 (0.0, 66.0) months, respectively. Once achieved, blood Phe levels remained below clinical threshold in most participants. Sustained Phe response (SPR), a new method described within for measuring durability of blood Phe response, was achieved by 85.5%, 84.7%, and 78.1% of blood Phe responders at blood Phe thresholds of ≤600, ≤360, or ≤ 120 μmol/L, respectively. Longer-term safety data were consistent with previous reports, with the most common adverse events (AEs) being arthralgia, injection site reactions, headache, and injection site erythema. The incidence of most AEs, including hypersensitivity AEs, was higher during the early treatment phase (≤6 months) than later during treatment. In conclusion, using data from three key pegvaliase clinical trials, participants treated with pegvaliase were able to reach clinically significant blood Phe reductions to clinical thresholds of ≤600, ≤360, or ≤ 120 μmol/L during early treatment, with safety profiles improving from early to sustained treatment. This study also supports the use of participant-level data and new ways of looking at durable blood Phe responses to better characterize patients' individual PKU treatment journeys.</p></div>","PeriodicalId":18814,"journal":{"name":"Molecular Genetics and Metabolism Reports","volume":"39 ","pages":"Article 101084"},"PeriodicalIF":1.9,"publicationDate":"2024-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214426924000375/pdfft?md5=0310037c2cca43a0f0c579050d3f6cae&pid=1-s2.0-S2214426924000375-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140637878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does administration of hydroxychloroquine/amiodarone affect the efficacy of enzyme replacement therapy for Fabry mice?","authors":"Takahiro Tsukimura ,&nbsp;Koki Saito ,&nbsp;Tomoko Shiga ,&nbsp;Yasuhiro Ogawa ,&nbsp;Hitoshi Sakuraba ,&nbsp;Tadayasu Togawa","doi":"10.1016/j.ymgmr.2024.101079","DOIUrl":"https://doi.org/10.1016/j.ymgmr.2024.101079","url":null,"abstract":"<div><p>As a standard therapy for Fabry disease, enzyme replacement therapy (ERT) with recombinant human α-galactosidase A (α-Gal) has been successfully used, and the instructions for this drug state that “it should not be co-administrated with cationic amphiphilic drugs such as hydroxychloroquine (HCQ) and amiodarone (AMI), since these drugs have the potential to inhibit intracellular α-Gal activity”. However, there would be cases in which HCQ or AMI is required for patients with Fabry disease, considering their medical efficacy and application.</p><p>Thus, we examined the impact of HCQ/AMI on recombinant human α-Gal by <em>in vitro</em>, cellular, and animal experiments. The results revealed that HCQ/AMI affected the enzyme activity of α-Gal incorporated into cultured fibroblasts from a Fabry mouse when the cells were cultured in medium containing these drugs and the enzyme, although their direct inhibitory effect on the enzyme is not strong. These lysosomotropic drugs may be trapped and concentrated in lysosomes, followed by inhibition of α-Gal.</p><p>On the other hand, no reduction of α-Gal activity incorporated into the organs and tissues, or acceleration of glycoshingolipid accumulation was observed in Fabry mice co-administered with HCQ/AMI and the enzyme, compared with in the case of usual ERT. As HCQ/AMI administered are catabolized in the liver, these drugs possibly do not affect ERT for Fabry mice, different from in the case of cultured cells in an environment isolated from the surroundings.</p></div>","PeriodicalId":18814,"journal":{"name":"Molecular Genetics and Metabolism Reports","volume":"39 ","pages":"Article 101079"},"PeriodicalIF":1.9,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214426924000326/pdfft?md5=78e0dfe3027f98ed2768fa315734a20a&pid=1-s2.0-S2214426924000326-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140347070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preventing hyperhomocysteinemia using vitamin B6 supplementation in Givosiran-treated acute intermittent porphyria: Highlights from a case report and brief literature review","authors":"Isabelle Redonnet-Vernhet ,&nbsp;Patrick Mercié ,&nbsp;Louis Lebreton ,&nbsp;Jean-Marc Blouin ,&nbsp;Didier Bronnimann ,&nbsp;Samir Mesli ,&nbsp;Claire Guibet ,&nbsp;Emmanuel Ribeiro ,&nbsp;Noémie Gensous ,&nbsp;Pierre Duffau ,&nbsp;Laurent Gouya ,&nbsp;Emmanuel Richard","doi":"10.1016/j.ymgmr.2024.101076","DOIUrl":"https://doi.org/10.1016/j.ymgmr.2024.101076","url":null,"abstract":"<div><p>Acute hepatic porphyrias are inherited metabolic disorders of heme biosynthesis characterized by the accumulation of toxic intermediate metabolites responsible for disabling acute neurovisceral attacks. Givosiran is a newly approved siRNA-based treatment of acute hepatic porphyria targeting the first and rate-limiting δ-aminolevulinic acid synthase 1 (ALAS1) enzyme of heme biosynthetic pathway. We described a 72-year old patient who presented with severe inaugural neurological form of acute intermittent porphyria evolving for several years which made her eligible for givosiran administration. On initiation of treatment, the patient developed a major hyperhomocysteinemia (&gt;400 μmol/L) which necessitated to discontinue the siRNA-based therapy. A thorough metabolic analysis in the patient suggests that hyperhomocysteinemia could be attributed to a functional deficiency of cystathionine β-synthase (CBS) enzyme induced by givosiran. Long-term treatment with vitamin B₆, a cofactor of CBS, allowed to normalize homocysteinemia while givosiran treatment was maintained. We review the recently published cases of hyperhomocysteinemia in acute hepatic porphyria and its exacerbation under givosiran therapy. We also discuss the benefits of vitamin B₆ supplementation in the light of hypothetic pathophysiological mechanisms responsible for hyperhomocysteinemia in these patients. Our results confirmed the importance of monitoring homocysteine metabolism and vitamin status in patients with acute intermittent porphyria in order to improve management by appropriate vitamin supplementation during givosiran treatment.</p></div>","PeriodicalId":18814,"journal":{"name":"Molecular Genetics and Metabolism Reports","volume":"39 ","pages":"Article 101076"},"PeriodicalIF":1.9,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214426924000296/pdfft?md5=c7aa4d6b699a612df40c6391fbbf9d27&pid=1-s2.0-S2214426924000296-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140343932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adiponectin overexpression improves metabolic abnormalities caused by acid ceramidase deficiency but does not prolong lifespan in a mouse model of Farber Disease","authors":"Marie K. Norris ,&nbsp;Trevor S. Tippetts ,&nbsp;Joseph L. Wilkerson ,&nbsp;Rebekah J. Nicholson ,&nbsp;J. Alan Maschek ,&nbsp;Thierry Levade ,&nbsp;Jeffrey A. Medin ,&nbsp;Scott A. Summers ,&nbsp;William L. Holland","doi":"10.1016/j.ymgmr.2024.101077","DOIUrl":"https://doi.org/10.1016/j.ymgmr.2024.101077","url":null,"abstract":"<div><p>Farber Disease is a debilitating and lethal childhood disease of ceramide accumulation caused by acid ceramidase deficiency. The potent induction of a ligand-gated neutral ceramidase activity promoted by adiponectin may provide sufficient lowering of ceramides to allow for the treatment of Farber Disease. In vitro, adiponectin or adiponectin receptor agonist treatments lowered total ceramide concentrations in human fibroblasts from a patient with Farber Disease. However, adiponectin overexpression in a Farber Disease mouse model did not improve lifespan or immune infiltration. Intriguingly, mice heterozygous for the Farber Disease mutation were more prone to glucose intolerance and insulin resistance when fed a high-fat diet, and adiponectin overexpression protected from these metabolic perturbations. These studies suggest that adiponectin evokes a ceramidase activity that is not reliant on the functional expression of acid ceramidase, but indicates that additional strategies are required to ameliorate outcomes of Farber Disease.</p></div>","PeriodicalId":18814,"journal":{"name":"Molecular Genetics and Metabolism Reports","volume":"39 ","pages":"Article 101077"},"PeriodicalIF":1.9,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214426924000302/pdfft?md5=ab99f39e5c5f7cf28d5765ac81433753&pid=1-s2.0-S2214426924000302-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140341142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}